CANCER IMMUNOLOGY RESEARCH

TABLE OF CONTENTS

WHAT WE'RE READING

IN THE SPOTLIGHT

REVIEW

PRIORITY BRIEF

RESEARCH ARTICLES

TABLE OF CONTENTS

TABLE OF CONTENTS

ABOUT THE COVER

Pancreatic neuroendocrine neoplasms (PNEN) are largely unresponsive to current immunotherapies. Zhong, Tian, and Wang et al. provide new insight into why this might be, showing that macrophages expressing CD276 (B7H3) suppress T-cell immunity in the PNEN tumor microenvironment. CD276 expression in macrophages is induced by the PIWI-interacting RNA piR-hsa-30937 in PNEN cell–derived small extracellular vesicles (sEV) through the PTEN/AKT pathway. piR-hsa-30937 knockdown and anti-CD276 treatment enhance $CD8^+$ T cell–mediated antitumor immunity in a preclinical model of PNEN, reducing tumor growth and metastasis, suggesting new approaches to consider for PNEN immunotherapy. Read more in this issue on page 840. Original image from Fig. 7C. Artwork by Lewis Long.





doi: 10.1158/2326-6066.CIR-12-7-CVR

NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR's established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.